From GlobeNewswire: 2025-05-30 16:15:00

Plus Therapeutics, Inc. reports financial results for Q1 2025, raising $15 million in private placement financing and appointing industry veterans to leadership positions. They also presented updated data on REYOBIQ™ at a conference and received FDA designation for the treatment of lung cancer patients. The Company’s cash balance was $9.9 million at the end of March 2025.

The Company completed Phase 1 clinical trials for REYOBIQ™, demonstrating safety and potential efficacy in treating glioblastoma. They also granted Orphan Drug Designation and received FDA agreement for the proprietary name. Plus Therapeutics also made progress with the CNSide™ CSF Assay Platform, appointing key leadership positions to support commercialization in 2025.

Financially, Plus Therapeutics reported a cash balance of $9.9 million at the end of Q1 2025, compared to $0.1 million in December 2024. They recognized $1.1 million in grant revenue during the quarter and reported a net loss of $17.4 million, or $(1.19) per share. The increase in operating loss was primarily due to legal fees.

Headquartered in Houston, Texas, Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for CNS cancers. Their product, REYOBIQ™, is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases. The Company aims to enhance clinical outcomes for patients with difficult-to-treat CNS cancers.



Read more at GlobeNewswire:: Plus Therapeutics Reports First Quarter Financial